NAIROBI, Kenya, March 11, 2026/APO Group/ —

• Findings were presented at the 2026 Roche Africa Press Day in Nairobi (https://www.Roche.com), which convened journalists from nine African countries with policymakers and health experts
• The event focused on the theme “Health is Wealth,” exploring how investment in women’s health can drive economic growth and stronger health system
• Research reveals every dollar invested in innovative breast cancer treatments generates up to USD 12.40 in economic return

 

Investing strategically in the health of Africa’s women will unlock billions of dollars in economic growth, as well as saving lives and strengthening communities, according to speakers at Africa Press Day held in Nairobi on March 4-5.

Convened by healthcare company Roche, the 2026 edition of Africa Press Day gathered journalists from nine African countries, alongside policymakers, economists, health experts, and development finance leaders. They discussed evidence and case studies proving how public private partnerships and strategic investments in health systems, especially in women’s health, can build human capital, productive workforces, and resilient economies.

In a keynote address, Kenya’s Principal Secretary State Department for Medical Services, Ministry of Health, Dr Ouma Oluga, urged media to help shape an informed narrative about improving health: “When a health story is being told, what is most important to portray? Is it what is killing people? Is it the solutions that should stop what is killing people? Or is it the in-between—the administrative, resource, and policy actions that link the two?”

As African governments increasingly focus on economic diversification and productivity, speakers argued that health investment must be treated as core economic policy — not simply a social expenditure.

Health is Wealth: The Economic Case for Investment 

To demonstrate the returns on investing in women’s health, Roche unveiled research (http://apo-opa.co/4b2mjzX) from the WifOR Institute showing how the aggressive form of HER2+ breast cancer (responsible for up to 20% of cases on the continent) caused over USD10 billion in lost productivity across seven African countries (Algeria, Côte d’Ivoire, Kenya, Morocco, Nigeria, South Africa, and Tunisia) from 2017-2023.

Nearly 90% of these losses came from women in their prime working years. The research also showed how every dollar invested in innovative cancer treatments can generate up to USD12.40 in economic returns, primarily by restoring women’s productivity and allowing for longer healthy working lives.

Maturin Tchoumi, Pharma International Area Head, Roche Africa, said: “Breast cancer is a rising threat to African societies and economies. The evidence clearly shows that investing in women’s health is not a cost or a social expense, but a powerful economic driver that underpins productivity, resilience, equity, and sustainable growth across the continent.”

Health Is Equity: Closing the Diagnosis Gap

Extending quality cancer care to all African women, regardless of geography or income, was a key theme of the event. This included closing the gaps in breast cancer screening and early diagnosis that lead to around 77 per cent (http://apo-opa.co/4cFcF7F) of African women being diagnosed in the later stages of the disease when it is much harder – and more expensive – to treat.

H.E. Dorothy Nyong’o, First Lady of Kisumu County, Chair of the Africa Cancer Foundation, and member of the Africa Breast Cancer Council, highlighted Kenya’s EMPOWER (http://apo-opa.co/4s7GuCH) initiative for breast and cervical cancer (which delegates visited at a local hospital). It has digitised the patient journey via 76 physical and virtual clinics, speeding up diagnosis and treatment. Since its founding in 2019, EMPOWER has reached over 235,000 women, enabling 3,225 to receive treatment, and been adopted by the National Cancer Institute of Kenya as a nationally integrated platform.

H.E. Dorothy Nyong’o said: “Tackling breast cancer is not just a moral issue; it’s a strategic choice. Kenya’s EMPOWER initiative highlights how partnership and digital innovation can create a step-change in women’s healthcare. It offers a blueprint to other African countries for public-private collaboration that drives systemic, equitable, and lasting change.”

Health is Resilience: Strengthening African Health systems

Throughout the 2026 Africa Press Day, speakers shared details of initiatives that are working to strengthen health systems, including:

• Women’s Integrated Care Services (WICs) in Kenya and Côte d’Ivoire, pilot projects that integrate women’s cancer services into primary health care for greater efficiency.
• Home grown pandemic preparedness efforts, including sustainable and integrated diagnostic facilities and laboratory networks.
• African-led science – including genomics and local research – that is contributing to African health sovereignty.

LAGOS, Nigeria, December 8, 2025/APO Group/ –Vestergaard Sàrl (www.Vestergaard.com) and Harvestfield Industries Limited today marked a historic milestone with the ground-breaking of a first-of-its-kind joint venture to transform malaria prevention and strengthen health security through direct investment in mosquito net manufacturing in Nigeria. The new joint venture, named SNG Health, will manufacture PermaNet® Dual, Vestergaard’s latest, dual active-ingredient pyrethroid-chlorfenapyr net designed to combat insecticide resistance. Production at the state-of-the-art facility is scheduled to begin in April 2026, with at-scale annual capacity of 10 million nets, creating 600 skilled jobs.

 

The ground-breaking ceremony took place at the site in Ogun State, with contributions from Dr Abdu Mukhtar, National Coordinator of the President’s Value Chain Initiative (PVAC); Dr Godwin Ntadom, Director of Public Health at the Federal Ministry of Health and Social Welfare; Dr Nnenna Ogbulafor, Director and National Coordinator of the National Malaria Elimination Programme; Ms Cornelia Camenzind, Consul General, Consulate General of Switzerland in Lagos, Nigeria; and Mr Onoriode Ezire, Task Team Leader, World Bank Nigeria.

 

Dr Abdu Mukhtar, National Coordinator of PVAC, said: “Nigeria is signalling that we are ready to lead the next frontier of malaria control in West Africa. This facility is a direct outcome of the Federal Government’s commitment to industrialize our health sector and anchor critical health products within the country. Every mosquito net produced here represents a Nigerian job, a Nigerian skill strengthened, and value created within our economy. This joint venture between Vestergaard and Harvestfield shows what responsible, future-focused partnership looks like. Today’s ground-breaking reaffirms our determination to ensure that lifesaving tools like PermaNet Dual are manufactured at scale, to global standards, and with long-term sustainability built into the system.”

 

Nigeria shoulders the world’s highest malaria burden, accounting for a quarter of all global cases and tragically, two out of every five children lost to malaria are Nigerian. While these are daunting statistics, new evidence from the Malaria Atlas Project shows we know what works: insecticide-treated nets have been instrumental in the fight against malaria, responsible for 72% of all malaria cases prevented (https://apo-opa.co/3KjuMEr) globally between 2000 and 2024. Notably, dual active-ingredient nets including PermaNet Dual have alone stopped 40 million cases from 2019 to 2024. These findings underscore that, though the challenge is immense, scaling up access to these proven, life-saving tools can unlock progress towards both national and global malaria control targets.

 

In March 2024, Nigeria signed the Yaoundé Declaration, pledging that “no one should die from malaria given the tools and systems available.” Today’s ground-breaking ceremony turns that pledge into action, building on the momentum from the memorandum of understanding (https://apo-opa.co/3KjuNbt) that was signed between the Nigerian Ministry of Health and Vestergaard last year, and turning technological advancements into tangible progress for a malaria-free generation.

 

Amar Ali, CEO of Vestergaard, said: “This facility embodies Vestergaard’s commitment to long-term partnership with Nigeria, demonstrating that private sector leadership can drive lasting impact. By directly investing in local production of PermaNet Dual—and putting our brand’s reputation behind this venture—we are not only delivering world-class innovation, but also ensuring families across Nigeria have quality protection against malaria. We believe that responsible enterprise must support African leadership in health by investing in local systems, training professionals and strengthening the capacity needed for countries to have the autonomy to protect the health of their own people.”

 

Martins Awofisayo, CEO of Harvestfield Industries, said: “Today marks an important step in strengthening Nigeria’s health security and industrial capacity. By partnering with Vestergaard to establish this facility in Nigeria, we are creating a reliable local source of world-class mosquito nets that will support malaria prevention efforts across the country. This investment is a testament to our commitment to saving lives, empowering communities, and building a sustainable manufacturing base for essential public health tools.”

 

Prosper Ndayiragije, Managing Director, SNG Health, said: “Today’s ground-breaking opens a new chapter of malaria control for Nigeria, underlining this country’s steadfast commitment to defeating this devastating disease. We are honoured to have the unwavering support of PVAC as we work together with Vestergaard and Harvestfield to make this initiative a reality. By manufacturing Vestergaard’s latest mosquito net innovation – PermaNet Dual – we are committed to doing our part to ensure that no Nigerian family will have to endure the burden of malaria in the future.”